Abstract

This study aimed to develop therapeutic drug monitoring (TDM) form based on analysis of pharmacists’ recommendation to address drug-related problems (DRPs) in chronic kidney disease (CKD) patients in a private hospital. The profile of DRPs and pharmacists’ recommendations, and clinical significance assessment of pharmacists’ recommendations before and after development of TDM form were compared. Focus group discussions (FGD) was undertaken to evaluate the TDM form. There was similar pattern of DRPs identified using either pre-developed or post-developed TDM form with dose selection being the most frequent DRP. No considerable difference regarding physician acceptance rate to pharmacists’ active recommendations before and after form development (70.6% and 65.4%, respectively). The commonest recommendations in both phases were dose change, drug discontinuation and drug change. There was no statistical difference regarding the clinical significance of recommendations between both phases but higher level of clinical significant recommendations was documented after form development. Major issues of pre-developed form identified during FGD including unclear instruction of documentation, inadequacy to justify the reasons for recommendations and non-integration within medical record. Development of TDM form unchanged the profile of DRPs and pharmacists’ recommendations, yet the developed form might generate more responses from other health professions and clinically significant recommendations.

Highlights

  • Chronic kidney disease (CKD) is a major health problem worldwide

  • This study aimed to develop therapeutic drug monitoring (TDM) form based on analysis of pharmacists’ recommendation to address drug-related problems (DRPs) in chronic kidney disease (CKD) patients in a private hospital

  • Major issues of pre-developed form identified during Focus group discussions (FGD) including unclear instruction of documentation, inadequacy to justify the reasons for recommendations and non-integration within medical record

Read more

Summary

INTRODUCTION

Chronic kidney disease (CKD) is a major health problem worldwide. A meta-analysis revealed that global CKD prevalence was estimated between 11%-13% (Hill et al, 2016). The identification and resolution of DRPs have beneficial effects on disease management, patient’s quality of life and healthcare cost (Ibrahim et al, 2013). One of pharmacists’ roles is to monitor drug therapy and give recommendations to address DRPs. Pharmacists’ recommendations have been signified as one Anggriani et al / Journal of Applied Pharmaceutical Science 8 (02); 2018: 071-078 of parameters in evaluating the importance of clinical pharmacy services (Kim and Schepes, 2003; Kim et al, 2014; Abdel-Qader et al, 2010; Ramadaniati et al, 2014a). The study hospital has used therapeutic drug monitoring (TDM) form since 2014 to document clinical pharmacists’ recommendation. This study aimed to develop TDM form based on analysis of pharmacists’ recommendation documentation to address DRPs in patients with CKD

MATERIAL AND METHODS
AND DISCUSSION
Findings
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call